Pyrimethamine Inhibits Human Ovarian Cancer by Triggering Lethal Mitophagy via Activating the p38/JNK/ERK Pathway
Altogether, these findings indicate that the antitumor effects of pyrimethamine result from the induction of lethal mitophagy via regulation of the p38/JNK/ERK pathway in ovarian cancer. Considering the low toxicity and high tolerance associated with pyrimethamine, it is suggested that pyrimethamine be evaluated in the treatment of ovarian cancer, either as a monotherapy or in combination with paclitaxel.
Authors
- Gang Zheng (ORCID: https://orcid.org/0009-0005-7320-5685)
- Lingjuan Linghu
- Hongying Zhou (ORCID: https://orcid.org/0000-0001-5383-8809)
- Tao Yi (ORCID: https://orcid.org/0000-0002-3309-8556)
Institutions
- Sichuan University (CN)
Publication Details
- Journal
- Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics
- Published
- 2025-01-01
- DOI
- https://doi.org/10.32604/or.2025.063724
- Primary Topic
- Quinazolinone synthesis and applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00